Lockheed Martin (LMT) Q3 2026 Earnings Call Transcript

Lockheed Martin reported Q3 2026 revenue of $20.7 billion, up 11% year over year, EPS of $7.97, up 15%, and record backlog of $292 billion. It raised 2026 sales guidance to $80–82 billion, EPS to $30.35–$30.75, and free cash flow to $7.8–8.0 billion; management cited expanding munitions production and growth across all four segments. The company increased its quarterly dividend by $0.15 to $3.60 per share, while noting that a pension contribution exceeding $1 billion is expected in 2027 and F-35 Lot 20 costs could pressure future results without additional U.S. government authorization and funding.

Analysis

The earnings signal is strongest in MFC’s conversion of demand into production, but the durable value depends on contract economics—not backlog size alone. Seven-year awards and cash-neutrality protections reduce ramp financing risk; however, final profit terms remain unresolved. If fixed-price escalators let Lockheed retain efficiency gains, automation and supplier investment could expand returns. If labor, yield, or supplier bottlenecks persist, volume can rise faster than profit. Boeing’s seeker award and L3Harris’s propulsion award provide demand visibility, but do not assume those contract values translate proportionally into consolidated earnings for either supplier.

The key near-term quality check is cash conversion: quarterly FCF benefited from working-capital collections, while management flagged a pension contribution exceeding $1B in 2027 and a tax-related cash tailwind that may moderate. Thus, reported FCF strength may not carry through at the same pace. Separately, shifted F-35 lot timing and costs incurred ahead of current authorization make funding and award timing a live risk, despite multi-year fleet visibility.

Over days, results support positive sentiment; over 1–3 months, watch final munitions contract terms, F-35 authorization/funding, and supplier delivery cadence. Over 6–18 months, successful capacity additions could broaden growth, but backlog remains exposed to appropriations timing and execution. Contrarian point: the market may overvalue record backlog as equivalent to funded, profitable revenue. Without valuation and current-price data, avoid chasing a gap higher; the thesis weakens if MFC profit growth trails sales or cash conversion disappoints versus guidance.

Key Decisions for Investors

• LMT: Favor a starter long on post-call weakness rather than chasing strength. Add only as MFC growth converts to operating profit and the final multi-year contract terms support management’s stated return framework; no price target is warranted without valuation data.
• Over the next 1–3 months, track MFC segment profit versus sales, contract finalization, and supplier delivery performance. Reassess the long thesis if volume ramps fail to produce corresponding profit growth or capacity milestones slip.
• Treat 2027 cash flow as a watch item: test guidance against the >$1B pension contribution, working-capital normalization, and fading tax tailwind. A material FCF shortfall versus the company’s outlook would challenge the earnings-quality thesis.
• Do not trade BA or LHX solely on the supplier awards; verify contract scope, timing, and segment-level contribution before attributing meaningful consolidated earnings upside.